Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer

Inclusion Criteria:

• Histologically proven epithelial carcinoma of the ovary or of the fallopian tube orextraovarian papillary serous carcinoma with extent to the ovary

• International Federation of Gynecology and Obstetrics (FIGO) stage IIB-IV, regardlessof measurable or non-measurable disease

• No prior chemo- or radiotherapy

• Adequate hematologic, renal and hepatic function:

• ANC ≥ 1.5 x 10^9/L,

• Platelet counts ≥ 100 x 10^9/L,

• Total bilirubin ≤ 1.5 x upper normal limit,

• Alkaline Phosphatase ≤ 3 x upper normal limit,

• Serum creatinine ≤ 1.25 upper normal limit,

• Estimated GFR ≥ 60 ml/min

• Performance status 0-2 (ECOG)

• Life expectancy must be greater than 12 weeks

Exclusion Criteria:

• Non-epithelial tumors or mixed epithelial/non-epithelial tumors (e.g. mixed Mulleriantumors) or tumors of low malignant potential (borderline tumors)

• Prior treatment with chemo- or radiotherapy

• Administration of other simultaneous chemotherapeutic drugs or hormonal therapy orsimultaneous radiotherapy during the study treatment period or planned whole abdominalradiotherapy

• History of congestive heart failure

• Symptomatic brain metastasis

• Complete bowel obstruction

• Dementia

• Active infection or other serious underlying medical condition

• Pre-existing motor or sensory neurologic pathology